Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity by Ranjithkumar Chellian et al.
fphar-07-00072 March 24, 2016 Time: 12:22 # 1
ORIGINAL RESEARCH
published: 30 March 2016
doi: 10.3389/fphar.2016.00072
Edited by:
Luyong Zhang,
China Pharmaceutical University,
China
Reviewed by:
Fang-Rong Chang,
Kaohsiung Medical University, Taiwan
Manoj Gajanan Kulkarni,
University of KwaZulu-Natal,
South Africa
*Correspondence:
Vijayapandi Pandy
pandiphd@gmail.com
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 17 December 2015
Accepted: 10 March 2016
Published: 30 March 2016
Citation:
Chellian R, Pandy V and Mohamed Z
(2016) Biphasic Effects of α-Asarone
on Immobility in the Tail Suspension
Test: Evidence for the Involvement
of the Noradrenergic
and Serotonergic Systems in Its
Antidepressant-Like Activity.
Front. Pharmacol. 7:72.
doi: 10.3389/fphar.2016.00072
Biphasic Effects of α-Asarone on
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the Noradrenergic and Serotonergic
Systems in Its Antidepressant-Like
Activity
Ranjithkumar Chellian, Vijayapandi Pandy* and Zahurin Mohamed
Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Alpha (α)-asarone is one of the main psychoactive compounds, present in Acorus
species. Evidence suggests that the α-asarone possess an antidepressant-like activity
in mice. However, the exact dose-dependent effect of α-asarone and mechanism(s)
involved in the antidepressant-like activity are not clear. The present study aimed to
investigate the dose-dependent effect of α-asarone and the underlining mechanism(s)
involved in the antidepressant-like activity of α-asarone in the mouse model of tail
suspension test (TST). In this study, the acute effect of α-asarone per se at different
doses (10–100 mg/kg, i.p.) on immobility in the TST was studied. Additionally, the
possible mechanism(s) involved in the antidepressant-like effect of α-asarone was
studied using its interaction with noradrenergic and serotonergic neuromodulators in
the TST. The present results reveal that the acute treatment of α-asarone elicited
biphasic responses on immobility such that the duration of the immobility time is
significantly reduced at lower doses (15 and 20 mg/kg, i.p.) but increased at higher
doses (50 and 100 mg/kg, i.p.) in the TST. Besides, α-asarone at higher doses
(50 and 100 mg/kg, i.p.) significantly decreased the spontaneous locomotor activity.
Moreover, pretreatment of mice with noradrenergic neuromodulators such as AMPT
(100 mg/kg, i.p., a catecholamine synthesis inhibitor), prazosin (1 mg/kg, i.p., an
α1-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an α2-adrenoceptor antagonist)
and with serotonergic neuromodulators such as PCPA (100 mg/kg, i.p., once daily for
four consecutive days, a serotonin synthesis inhibitor,) and WAY100635 (0.1 mg/kg,
s.c., a selective 5-HT1A receptor antagonist) significantly reversed the anti-immobility
effect of α-asarone (20 mg/kg, i.p.). Taken together, our results suggest that the acute
treatment with α-asarone elicited biphasic actions in the TST in which antidepressant-
like effect was seen at relatively lower doses (15 and 20 mg/kg, i.p.) and depressive-like
activity at relatively higher doses (50 and 100 mg/kg, i.p.). Furthermore, it has been
revealed that the antidepressant-like effect of α-asarone could be mediated through
both noradrenergic (α1 and α2 adrenoceptors) and serotonergic (particularly, 5-HT1A
receptors) systems.
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INTRODUCTION
Alpha (α)-asarone [1,2,4-trimethoxy-5-[(E)-pro-1-enyl]
benzene; Pubchem CID: 636822; Figure 1), is one of the main
pharmacologically active compounds present in Acorus calamus
Linn (Acoraceae), Acorus tatarinowii Schott (Acoraceae), and
Acorus gramineus Solander (Acoraceae; Rajput et al., 2014).
The various neuropharmacological activities of α-asarone in
numerous preclinical studies were reported in the literature
including anticonvulsant (Huang et al., 2013), neuroprotective
(Limon et al., 2009), anxiolytic (Liu et al., 2012), and nootropic
effects (Limon et al., 2009; Kumar et al., 2012). Recently,
the antidepressant-like effect of an essential oil from Acorus
tatarinowii Schott have been reported in well-validated animal
models of depression such as TST and forced swim test (FST).
In the same study, the acute treatment of α-asarone at lower
doses (10 and 20 mg/kg, i.p.) showed an antidepressant-like
activity in both established mouse models (Han et al., 2013).
Besides that, other reports claimed that α-asarone possess CNS
depressant-like effect whereby mice treated with α-asarone at
higher doses (≥50 mg/kg, i.p.) affected locomotor activity and
potentiated the pentobarbitone-induced sleeping time, a test
that is used for the screening of potential CNS depressants
(Menon and Dandiya, 1967; Pages et al., 2010; Liu et al., 2012).
Similarly, CNS depressant-like activity of roots, rhizome and
leaf extracts of Acorus calamus have been reported (Motley,
1994; Pandy et al., 2009). In our previous study, Acorus calamus
leaf extracts significantly increased the immobility time in FST,
and diazepam-induced sleeping time and significantly reduced
the spontaneous locomotor activity without affecting motor
coordination (Pandy et al., 2009). Conversely, antidepressant-
like activities of methanolic extract of rhizomes and leaves of
Acorus calamus in FST and TST have been reported in other
studies (Pawar Vinod et al., 2012; Pushpa et al., 2013). These
seemingly contradictory reports led us to try and find answers by
conducting further studies to determine dose-dependent effect
of α-asarone, the active phytoconstituent of Acorus species, at
doses that are beyond those that have been reported, which is
more than 20 mg/kg in the TST. Additionally, the underlying
mechanism(s) involved in the antidepressant-like activity of
α-asarone was examined using its interaction with noradrenergic
neuromodulators such as AMPT, prazosin, and yohimbine
and serotonergic neuromodulators PCPA and WAY100635 in
the TST.
MATERIALS AND METHODS
Animals
Adult male, ICR mice (Institute for Cancer Research) of age
8–10 weeks, bred and supplied by the Animal Experimental
Unit (AEU, Faculty of Medicine, University of Malaya, Kuala
Lumpur) were used in all our experiments. The mice were
Abbreviations: CNS, central nervous system; GABA, gamma-aminobutyric acid;
5-HT, 5- hydroxytryptamine; i.p., intraperitoneal injection; s.c., subcutaneous
injection; TST, tail suspension test.
FIGURE 1 | Chemical structure of α-asarone (1, 2,
4-trimethoxy-5-[(E)-pro-1-enyl] benzene).
housed (four mice per cage) in an individually ventilated
cage at the Satellite Animal Facility (SAF), Department of
Pharmacology, Faculty of Medicine, University of Malaya, Kuala
Lumpur, and acclimatized for a week in a controlled environment
[22 ± 2◦C, 50–70% humidity and 12 h light/dark (lights on at
7.00 am)] with food and water available ad libitum. AEU and
SAF have been accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC). All experimental protocols adhered to the guidelines
of the National Research Council of the National Academies
of the USA (“Guide for the Care and Use of Laboratory
Animals,” Eighth Edition; Garber et al., 2011) and were assessed
and approved by the Faculty of Medicine-Institutional Animal
Care and Use Committee (FOM-IACUC), University of Malaya
(Ethics Approval no: 2014-10-14/PHAR/R/VP). The behavioral
experiments were performed during the light cycle between 10.00
am and 6.00 pm. All efforts were made to minimize suffering
in the mice, and to reduce the number of mice used in the
experiments.
Drugs and Treatment
The following drugs were used: α-asarone (Lot # S18779V;
Purity 98% w/w), Tween 80 (polyethylene sorbitan monooleate;
Lot # MKBP0682V; Purity ≥ 99% v/v), α-methyl-p-tyrosine
(AMPT; Lot # STBD4408V; Purity 98% w/w), and 4-chloro-
D-L-phenylalanine methyl ester hydrochloride (PCPA or
Fenclonine; Lot # SHBD9164V; Purity 97% w/w) ± 8-hydroxy-
2-dipropylamino tetralin hydrobromide (8-OH-DPAT; Lot
# 053M4102V; Purity ≥ 98% w/w), prazosin hydrochloride
(Lot # 129K1137V; Purity ≥ 99% w/w) and yohimbine
hydrochloride (Lot # 13CBM8231V; Purity ≥ 98% w/w;
purchased from Sigma-Aldrich, St. Louis, MO, USA); bupropion
hydrochloride (Lot #2596608; Purity ≥ 99.5% w/w) and
fluoxetine hydrochloride (Lot #2597489; Purity 99.8% w/w;
obtained from LKT laboratories, Inc., St. Paul, MN, USA);
N-[2-[4-(2-methoxyphenyl) piperazin-1-yl] ethyl]- N-pyridin-
2-ylcyclohexanecarcoxamide hydrochloride (WAY100635; Lot #
6-GJF-12-1; Purity 98% w/w; purchased from Toronto Research
Chemicals, Inc., Toronto, ON, Canada). The α-asarone was
suspended in 5% v/v Tween 80 prepared in normal saline.
Bupropion, fluoxetine, PCPA, WAY100635, 8-OH-DPAT,
prazosin and yohimbine were dissolved in normal saline and
AMPT was suspended in 10% v/v Tween 80 prepared in normal
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saline. All the drugs were administered i.p., whereas WAY100635
was administered s.c. on a constant dose volume of 10 mL/kg
body weight of mice. The mice in the control group received
the appropriate vehicle used in this study. The administration
schedule and dose of drugs used in this study was chosen as
reported in the published literature and standardized in our
laboratory.
Behavioral Procedures
Tail Suspension Test
The TST was performed for 6 min as described previously (Steru
et al., 1985). Briefly, both acoustically and visually isolated mice
were suspended 25-cm above the floor by adhesive tape placed
approximately 1 cm from the tip of the tail. Mice were considered
immobile when they hung passively and completely motionless.
The motionless hanging posture represents depression-like
behavior of the animals. The experiment was recorded and
monitored using a Logitech webcam (C270) connected to
a personal computer and the immobility time in second
was measured using a digital stop-watch during the 6 min
test by an experienced observer (blinded to the experiment).
Antidepressants decrease the immobility time in the TST (Steru
et al., 1985).
Horizontal Wire Test
The experiment was performed as described previously (Jung
et al., 2013) with slight modifications. The mouse was lifted by
the tail and the forepaws were allowed to grasp the center of the
horizontal metallic wire (2 mm diameter, 70 cm long) suspended
in the air about 40 cm from the surface of the table and then
the tail was released to let the mouse to hang with its forelimb.
The ability of the mouse to actively grasp the wire within the
first 10 s (grasping reflex) and hang on, or climb up within 20 s
test was measured. The mouse which tends to grasp, hang or
climb-up, was considered as a normal motor coordination. On
the other hand, mouse which failed to grasp or fall off from the
wire within 20 s was considered as mouse with impaired motor
coordination. The data are expressed as % of mice with normal
motor coordination.
Spontaneous Locomotor Activity
The spontaneous locomotor activity was assessed using actimeter
(Model: ACT-01, Orchid’s Scientific, Nasik, India) fabricated
with clear square Plexiglas arena (50 cm × 50 cm), equipped
with 32-infrared sensors. The mouse was placed in the center
of the arena and the locomotor activity was measured for the
duration of 10 min. The data are expressed as the total light beam
interruptions (locomotor counts). The floor of the apparatus was
cleaned with 20% v/v ethanol between tests.
Experimental Design
Effect of α-Asarone per se in the TST
The mice were divided into eight groups (N = 10). Thirty
minutes after acute treatment with the vehicle (5% v/v Tween 80)
or with bupropion (20 mg/kg, i.p.) as a positive control or the test
compound α-asarone (10, 15, 20, 30, 50, and 100 mg/kg, i.p.), the
immobility time in seconds was measured in the TST.
Effect of α-Asarone in the Horizontal Wire Test
The mice were assessed for motor coordination in the horizontal
wire test. Briefly, seven groups (N = 9–10) were treated with an
acute dose of vehicle (5% v/v Tween 80) or with α-asarone (10,
15, 20, 30, 50, and 100 mg/kg, i.p.). Thirty minutes after acute
treatment with vehicle or α-asarone, the horizontal wire test was
performed.
Effect of α-Asarone in the Spontaneous Locomotor
Activity
The mice were divided into seven groups (N = 9–10). Thirty
minutes after acute treatment with vehicle (5% v/v Tween 80)
or α-asarone (10, 15, 20, 30, 50, and 100 mg/kg, i.p.), the
spontaneous locomotor activity was assessed for 10 min in
actimeter.
Investigation of the Involvement of
Noradrenergic System in the
Antidepressant-Like Effect of α-Asarone
To investigate the involvement of the noradrenergic system
in the antidepressant-like activity of α-asarone, the mice
were pretreated with saline, or AMPT (100 mg/kg, i.p., a
catecholamine synthesis inhibitor). Four hours after AMPT
administration, mice were treated with either vehicle (5% v/v
Tween 80) or bupropion (20 mg/kg, i.p.) or α-asarone (20 mg/kg,
i.p.). Thirty minutes after vehicle or drug treatment, TST
was performed (Machado et al., 2008; Kwon et al., 2010). In
another study, the mice were pretreated with saline or prazosin
(1 mg/kg, i.p., an α1-adrenoceptor antagonist) or yohimbine
(1 mg/kg, i.p., an α2-adrenoceptor antagonist). Thirty minutes
after administration of saline or prazosin, or yohimbine, mice
were treated with either vehicle (5% v/v Tween 80) or α-asarone
(20 mg/kg, i.p.). Thirty minutes after vehicle or α-asarone
treatment, the immobility time in seconds was measured in the
TST (Colla et al., 2012; Zeni et al., 2013).
Investigation of the Involvement of
Serotonergic System in the
Antidepressant-Like Effect of α-Asarone
To assess the involvement of serotonergic system in the
antidepressant-like activity of α-asarone, the mice were
pretreated with saline, or PCPA (100 mg/kg, i.p., a serotonin
synthesis inhibitor, once daily for four consecutive days). On day
5 (24 h after last PCPA treatment), mice received either vehicle
(5% v/v Tween 80) or fluoxetine (30 mg/kg, i.p.) or α-asarone
(20 mg/kg, i.p.) 30 min prior to TST (Machado et al., 2009;
Kwon et al., 2010). In another study, the mice were pretreated
with either saline or WAY100635 (0.1 mg/kg, s.c., a selective
5-HT1A receptor antagonist). Thirty minutes after saline or
WAY100635 treatment, the mice were administered with either
vehicle (5% v/v Tween 80) or 8-OH-DPAT (1 mg/kg, i.p., a
selective 5-HT1A receptor agonist) or α-asarone (20 mg/kg, i.p.).
The immobility time in seconds was measured after 30 min of
vehicle or 8-OH-DPAT or α-asarone (Talbot et al., 2010; Colla
et al., 2012).
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Statistical Analysis
Values are expressed as mean ± SEM. The behavioral tests were
analyzed by one-way ANOVA followed by post hoc Dunnett’s
multiple comparison test or two-way analysis of variance (two-
way ANOVA) followed by post hoc Bonferroni test using
Graphpad prism 5.03 (Graphpad Software, Inc., USA). Statistical
significance was set at p< 0.05.
RESULTS
Effect of α-Asarone per se in the TST
As shown in (Figure 2), one-way ANOVA results revealed that
the acute treatment of α-asarone at relatively lower doses (15
and 20 mg/kg, i.p.) and the reference antidepressant, bupropion
(20 mg/kg, i.p.) significantly reduced the immobility time in
the TST. In contrast, α-asarone at relatively higher doses (50
and 100 mg/kg, i.p.) significantly increased the immobility time
in the TST as compared with vehicle control [F(6,62) = 15.30,
p< 0.0001].
Effect of α-Asarone per se in the
Horizontal Wire Test
The results of the horizontal wire test revealed that α-asarone (10,
15, 20, 30, 50, and 100 mg/kg, i.p.) did not alter the normal motor
coordination that is, it did not affect the grasping reflex, hanging
or climbing behavior (data not shown).
Effect of α-Asarone per se on the
Spontaneous Locomotor Activity
As shown in (Figure 3), one-way ANOVA results revealed that
α-asarone at lower doses (10, 15, 20, and 30 mg/kg, i.p.) did not
FIGURE 2 | Tail suspension test. Effect of the acute treatment of α-asarone
(10, 15, 20, 30, 50, and 100 mg/kg, i.p.) per se and bupropion (20 mg/kg,
i.p.) on the immobility time of mice in the TST. Data are expressed as
mean ± SEM (n = 10). The statistical difference between vehicle and
α-asarone or bupropion was analyzed using one-way ANOVA followed by
post hoc Dunnett’s multiple comparison test. ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001 as compared with vehicle-control group.
FIGURE 3 | Spontaneous locomotor activity. Effect of the acute treatment
of α-asarone (10, 15, 20, 30, 50, and 100 mg/kg, i.p.) per se on the
spontaneous locomotor activity in mice. Values are expressed as
mean ± SEM (n = 9–10). The statistical difference between vehicle control
and α-asarone treated groups was analyzed using one-way ANOVA followed
by post hoc Dunnett’s multiple comparison test. ∗∗p < 0.01 and ∗∗∗p < 0.001
as compared with the vehicle-control group.
significantly affect the spontaneous locomotor activity, whereas
relatively higher doses of α-asarone (50 and 100 mg/kg, i.p.)
significantly decreased locomotor activity when compared with
the vehicle control group [F(6,60) = 8.363, p< 0.0001].
Involvement of the Noradrenergic
System in the Antidepressant-Like Effect
of α-Asarone
The results depicted in (Figure 4A) shows that the anti-
immobility effect of α-asarone (20 mg/kg, i.p.) and positive
control, bupropion (20 mg/kg, i.p.) was significantly blocked
in AMPT (100 mg/kg, i.p.)-pretreated mice in the TST. Two-
way ANOVA results revealed that there was a significant effect
on AMPT pretreatment [F(2,42) = 12.82, p < 0.0001], α-asarone
or bupropion treatment [F(1,42) = 72.92, p < 0.0001] and
α-asarone or bupropion × AMPT interaction [F(2,42) = 6.20,
p < 0.0044]. Moreover, mice pretreated with prazosin (1 mg/kg,
i.p.) significantly reversed the anti-immobility effect of α-asarone
(20 mg/kg, i.p.) in the TST. Two-way ANOVA results showed
a significant effect on prazosin pretreatment [F(1,27) = 7.47,
p < 0.0109], α-asarone treatment [F(1,27) = 25.76, p < 0.0001]
and α-asarone× prazosin interaction [F(1,27) = 6.50, p< 0.0168;
Figure 4B]. Figure 4C shows that yohimbine (1 mg/kg,
i.p.) pretreatment significantly inhibited the anti-immobility
effect of α-asarone (20 mg/kg, i.p.) in the TST. Two-way
ANOVA results revealed a significant effect on α-asarone
treatment [F(1,26) = 9.41, p = 0.0050], α-asarone × yohimbine
interaction [F(1,26) = 5.43, p < 0.0278], but not with yohimbine
pretreatment [F(1,26) = 2.77, p= 0.1082].
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FIGURE 4 | Involvement of noradrenergic system in the
antidepressant-like activity of α-asarone. Effect of pre-treatment of mice
with (A) AMPT (100 mg/kg, i.p., a catecholamine synthesis inhibitor) or (B)
prazosin (1 mg/kg, i.p., an α1-adrenoceptor antagonist) or (C) yohimbine
(1 mg/kg, i.p., an α2-adrenoceptor antagonist) on α-asarone (20 mg/kg, i.p.)-
induced anti-immobility in the TST. Values are expressed as mean ± SEM
(n = 8). The immobility time was analyzed using two-way ANOVA followed by
post hoc Bonferroni test. ∗∗p < 0.01, and ∗∗∗p < 0.001 as compared with the
vehicle group. ##p < 0.01 as compared with α-asarone (20 mg/kg, i.p.) per
se, ###p < 0.001 as compared with the group treated with α-asarone
(20 mg/kg, i.p.) or bupropion (20 mg/kg, i.p.) per se.
Involvement of the Serotonergic System
in the Antidepressant-Like Effect of
α-Asarone
The anti-immobility effect of α-asarone (20 mg/kg, i.p.) or
positive control, fluoxetine (30 mg/kg, i.p.) in the TST was
prevented in PCPA (100 mg/kg, i.p., once daily for four
consecutive days)-pretreated mice (Figure 5A). Two-way
ANOVA results revealed that there was a significant effect of
α-asarone or fluoxetine treatment [F(1,42) = 17.98, p < 0.0001],
α-asarone or fluoxetine × PCPA interaction [F(2,42) = 5.02,
p < 0.0111], and not with PCPA pretreatment [F(2,42) = 1.38,
p = 0.2630]. Besides that, mice pretreated with WAY100635
(0.1 mg/kg, s.c.) reversed the anti-immobility effect of α-asarone
(20 mg/kg, i.p.) or 8-OH-DPAT (1 mg.kg, i.p.; Figure 5B).
The two-way ANOVA results revealed a significant effect
of WAY100635 pretreatment [F(2,41) = 3.52, p = 0.0390],
α-asarone or 8-OH-DPAT treatment [F(1,41) = 15.45,
p = 0.0003], α-asarone or 8-OH-DPAT × WAY100635
interaction [F(2,41) = 7.44, p= 0.0018].
DISCUSSION
Depression is a heterogeneous affective disorder which
particularly affects the mood and is associated with
high rates of recurrence, relapses, and premature deaths.
Globally, up to 20% of population are affected with major
depression (Berton and Nestler, 2006). The TST is a well-
validated and widely used animal model to screen potential
antidepressants. It is an inexpensive, highly predictive, and
is considered a high-throughput screening for the acute
behavioral effects of antidepressants (O’Leary and Cryan,
2009).
The present TST results demonstrate that acute treatment of
α-asarone at relatively lower doses (15 and 20 mg/kg, i.p.) showed
an antidepressant-like effect in the mouse model of depression.
This result is in accordance with the recent literature reported
by Han et al. (2013) in which a significant antidepressant-like
effect of α-asarone was demonstrated in both the FST and TST
at doses of 10 and 20 mg/kg, i.p. However, α-asarone at relatively
higher doses (50 and 100 mg/kg, i.p.) significantly increased the
immobility time in the TST.
Furthermore, in order to eliminate false positive results
of psychostimulant-like substances in the TST, the effect of
α-asarone on spontaneous locomotor activity in mice was
assessed. These results revealed that α-asarone (10–30 mg/kg,
i.p.) did not affect the spontaneous locomotor activity, suggesting
that the anti-immobility effect of α-asarone (15 and 20 mg/kg,
i.p.) in the TST could not have been mediated through
stimulation of the CNS. Moreover, α-asarone at higher doses
(50 and 100 mg/kg, i.p.) significantly decreased the spontaneous
locomotor activity and this result is in good agreement with the
previous findings in which acute treatment of α-asarone (48,
50, and 100 mg/kg, i.p.) significantly decreased the locomotor
activity in mice (Menon and Dandiya, 1967; Pages et al., 2010;
Liu et al., 2012).
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FIGURE 5 | Involvement of serotonergic system in the
antidepressant-like activity of α-asarone. Effect of pre-treatment with
(A) PCPA (100 mg/kg, i.p., once daily for four consecutive days, a serotonin
synthesis inhibitor) or (B) WAY100635 (0.1 mg/kg, s.c., a selective 5-HT1A
receptor antagonist) on α-asarone (20 mg/kg, i.p.)- induced anti-immobility in
the TST. Values are expressed as mean ± SEM (n = 8). The immobility time
was analyzed using two-way ANOVA followed by post hoc Bonferroni test.
∗∗p < 0.01 and ∗∗∗p < 0.001 as compared with the vehicle group. #p < 0.05
as compared with the α-asarone (20 mg/kg, i.p.) per se, ##p < 0.01 as
compared with the α-asarone (20 mg/kg, i.p.) or fluoxetine (30 mg/kg, i.p.) per
se and ###p < 0.001 as compared with 8-OH-DPAT (1 mg/kg, i.p.) per se.
In addition, α-asarone (10–100 mg/kg, i.p.) did not affect the
normal motor coordination as indicated in the horizontal wire
test, thus alluding to absence of muscle relaxant property of
α-asarone up to a dose of 100 mg/kg. This result corroborates
with the previous report by Pages et al. (2010) which
demonstrated that the motor coordination of mice was not
affected when the mice were pretreated with α-asarone (22
and 60 mg/kg, i.p.) in the rotarod test. Therefore, it can be
suggested that the increased immobility time in the TST, and
a reduction in spontaneous locomotor activity at higher doses
of α-asarone (50 and 100 mg/kg, i.p.) could be attributed to
its depressant-like effect and not due to any muscle relaxant
effect. The present study, however, could not clarify the exact
mechanism(s) involved in the depressant-like effect of α-asarone
at relatively higher doses. Based on our thorough literature
search, it is postulated that GABAergic mediated mechanism
could be involved in the depressant-like effect of α-asarone at
higher doses. In earlier studies, α-asarone at relatively higher
doses showed antiepileptic activity mediated through GABAergic
mechanism in pentylenetetrazole or picrotoxin-induced seizures
in mice (Pages et al., 2010). Similarly, the electrophysiological
studies (Huang et al., 2013; Wang et al., 2014) also confirmed the
facilitatory effect of α-asarone on GABAA receptors.
The monoamine theory of depression was proposed by
Schildkraut (1965) and states that depression is caused by
functional deficit of the monoamine neurotransmitters mainly
noradrenaline (NA) and/or serotonin. The currently available
antidepressants which are very effective in treating major
depression including monoamine oxidase inhibitors (MAOIs),
tricyclic antidepressants (TCAs), selective serotonin reuptake
inhibitors (SSRIs), noradrenaline reuptake inhibitors (NRIs) and
serotonin and noradrenaline reuptake inhibitors (SNRIs). The
key mechanism(s) of action of all of these drugs are similar, that
is, by enhancing the brain’s noradrenergic and/or serotonergic
transmissions (Berton and Nestler, 2006; Moret and Briley, 2011).
Thus, the monoamine theory of depression is still considered a
promising tool in the novel drug discovery for the treatment of
major depressive disorder.
Down regulation of the central noradrenergic system and
the ensuing reduction of brain noradrenaline level are the main
key factors responsible for the pathophysiology of depressive
disorder (Moret and Briley, 2011). AMPT is an inhibitor of
tyrosine hydroxylase, a rate limiting enzyme in the biosynthesis
of noradrenaline and dopamine (Widerlov and Lewander, 1978).
Mice pretreated with AMPT showed a significant reduction in the
brain noradrenaline and dopamine levels without affecting the
levels of serotonin (Mayorga et al., 2001). It has also been reported
that AMPT pretreated mice demolished the antidepressant
activity of bupropion (a non-selective noradrenaline and
dopamine reuptake inhibitor) in the TST (Kwon et al., 2010).
Moreover, several studies elucidated the involvement of α1,
and α2- adrenoceptors in the antidepressant-like effect of drugs
in animal behavioral models of depression (Machado et al.,
2009; Capra et al., 2010; Goncalves et al., 2012; Zeni et al.,
2013). Evidence suggested that the brain α1-adrenoceptors were
desensitized in the depressed patients and that the activation of
α1- adrenoceptors restored the normal mood (Stone et al., 2003).
In addition, chronic treatment with TCAs enhanced the density
of α1- adrenoceptors (Stone et al., 2003) and importantly, the
antidepressant effect of desipramine (a TCA) was blocked in the
mice pretreated with prazosin (an α1-adrenoceptor antagonist)
in the FST (Danysz et al., 1986). Furthermore, antagonism
of presynaptic α2-adrenoceptors enhanced the noradrenaline
levels and on the other hand, activation of post-synaptic α2-
adrenoceptors facilitated the antidepressant-like effect (Zhang
et al., 2009). Similarly, the antidepressant-like effect of clonidine
(an α2-adrenoceptors agonist) was inhibited by yohimbine
(α2-adrenoceptor antagonist) in the FST (O’Neill et al., 2001). It
has also been found that the α2-adrenoceptors were up-regulated
in depressed patients and that chronic antidepressant therapy
decreased its up-regulation (Flügge et al., 2003). These evidences
suggested the importance of the noradrenergic (α1 and α2
adrenoceptors) system for effective antidepressant therapy. In the
present study, the mice pretreated with AMPT (a catecholamine
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synthesis inhibitor) prevented the antidepressant-like effect of
α-asarone and in addition, the mice pretreated with prazosin (an
α1-adrenoceptor antagonist) and yohimbine (α2-adrenoceptor
antagonist) also abolished the antidepressant-like activity of
α-asarone, indicating the involvement of the noradrenergic (α1
and α2 adrenoceptors) system in the antidepressant-like effect of
α-asarone.
The down-regulation of brain serotonergic system is strongly
implicated in depressive disorder (Mann, 2013). PCPA, a selective
serotonin synthesis inhibitor, inhibits tryptophan hydroxylase
and depletes serotonin level in the brain without affecting
the brain noradrenaline and dopamine levels (Redrobe et al.,
1998). Several studies highlighted that the pretreatment of
PCPA inhibited the antidepressant-like effect of fluoxetine (a
selective serotonin reuptake inhibitor) in the TST and FST
(Machado et al., 2009; Kwon et al., 2010). The Positron
emission tomography with [11C] WAY100635 in depressed
patients revealed a decreased expression of 5-HT1A receptors in
several brain regions including frontal cortex and hippocampus
(Drevets et al., 1999; Sargent et al., 2000). Furthermore, one
of the mechanisms involved in the antidepressant-like effect
of MAOI, TCAs, or SSRIs is mediated by its interaction
with 5-HT1A receptors (Hensler, 2002). In another study, it
was found that the 5-HT1A knockout mice treated with the
fluoxetine or paroxetine (SSRIs) did not decrease the immobility
time whereas desipramine (TCA) decreased the immobility in
the TST (Mayorga et al., 2001), which clearly suggested the
importance of 5-HT1A receptors in the antidepressant effect of
SSRIs.
In the present study, the mice pretreated with PCPA
(a selective serotonin synthesis inhibitor) blocked the
antidepressant-like effect of α-asarone. Furthermore,
pretreatment of mice with WAY100635 (a 5-HT1A antagonist)
abolished the antidepressant-like effect of α-asarone. These
results demonstrated the involvement of the serotonergic
(particularly the 5-HT1A receptors) system in the antidepressant-
like effect of α-asarone.
In summary, our study demonstrate that acute treatment
of α-asarone exhibited antidepressant-like activity at relatively
lower doses (15 and 20 mg/kg, i.p.) without affecting either
locomotor activity or motor coordination in mice. On the other
hand, α-asarone at relatively higher doses (50 and 100 mg/kg,
i.p.) significantly enhanced the immobility time in the TST and
diminished the spontaneous locomotor activity which indicates
a depressive-like effect of α-asarone at higher doses. Moreover,
the antidepressant-like effect of α-asarone was prevented in the
mice pretreated with AMPT or prazosin or yohimbine or PCPA
or WAY100635, thereby indicating the involvement of both the
noradrenergic and serotonergic systems in the antidepressant-
like effect of α-asarone.
CONCLUSION
This study results indicates that acute treatment of α-asarone
exhibited a biphasic effect on the immobility time in the TST,
with an antidepressant-like activity at lower doses and depressive-
like effect at higher doses. The antidepressant-like effect of
α-asarone is mediated by its interaction with noradrenergic (α1
and α2 adrenoceptors) and serotonergic (particularly, the 5-HT1A
receptors) systems. Therefore, we suggest that α-asarone could be
singled out and further tested as a potential drug for the treatment
of major depressive disorder.
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